Remove 2020 Remove Company Focus Remove Regulations
article thumbnail

Three Drivers of the M&A Rebound in 2H 2020

Velocity Global

M&A activity dropped during the first two quarters of 2020 after COVID-19 created economic conditions not seen since the Great Depression. As the business world adjusts to the new normal, executives regained confidence in their companies’ outlook and the global economy. Non-financial corporations in the U.S.

Payroll 52
article thumbnail

Combining In-House & Remote Teams: Finding the Right Balance

NoonDalton

In 2020, everyone was talking about finding the best way to make remote teams work. While people are feeling safe enough to start gathering in person again, it doesn’t seem likely that companies will be able to revert back to the “old” ways quite so quickly. No two companies are created equal.

professionals

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How France is Leading the Race for European Unicorns

Globalization Partners

Macron’s broader goal is to achieve 100 French unicorns by 2030, including 25 green unicorns (companies focused on creating technology that will reduce human impact on the environment). French tech companies raised EUR 11.6 This was an increase of 115 percent against 2020. billion in funds in 2021. How G-P can help.

article thumbnail

The Case for Going Asset-Light in 2021

Velocity Global

The global economy was thrown into disarray in 2020, exposing critical supply chain vulnerabilities and causing businesses to rethink strategies. According to a recent Accenture report, 94% of Fortune 1000 companies said the pandemic led to supply chain disruptions, while 75% said COVID-19 negatively affects their businesses.

Payroll 52
article thumbnail

Six innovation strategies for Life Science organizations in 2023

IBM Services

The first AI-designed drug candidate to enter clinical trials was reported by Exscientia in early 2020. Since then, companies such as Insilico Medicine, Evotec and Schrödinger have announced phase I trials. Bills and regulations will increase the adoption and application of AI AI underpins the trends mentioned above.